天眼查App显示，近日，海南诸睿熹生物科技有限公司成立，法定代表人为龙莲英，注册资本300万人 民币，经营范围为一般经营项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广； 农作物秸秆处理及加工利用服务；货物进出口；进出口代理；生物基材料制造；生物基材料销售；密封 用填料制造；密封用填料销售；农副产品销售；初级农产品收购；食用农产品初加工；基础化学原料制 造（不含危险化学品等许可类化学品的制造）；专用化学产品制造（不含危险化学品）；新材料技术研 发；轻质建筑材料制造；轻质建筑材料销售；生物基材料技术研发（经营范围中的一般经营项目依法自 主开展经营活动，通过国家企业信用信息公示系统（海南）向社会公示）。 ...

（股份代號：6996） 自願公告 希維奧®在香港獲批用於治療多發性骨髓瘤 及瀰漫大B細胞淋巴瘤兩種新增適應症 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Antengene Corporation Limited 德琪醫藥有限公司 （於開曼群島註冊成立的有限公司） 德琪醫藥有限公司（簡稱「德琪醫藥」，香港交易所股票代碼：6996.HK）是一家以 研發為驅動的全球商業化階段生物科技公司，專注於開發治療具有未獲滿足的大 量醫療需求的疾病的同類首款和同類最優療法。其產品管線涵蓋臨床前階段到商 業化階段並包括多個內部開發項目，當中包括ATG-022（CLDN18.2抗體藥物偶聯 物）、ATG-037（口服CD73抑制劑）、ATG-101（PD-L1 × 4-1BB雙特異性抗體）、 ATG-031（靶向CD24巨噬細胞激活劑）及ATG-042（口服PRMT5-MTA抑制劑）。 德琪醫藥亦開發了AnTenGager™，其為專有的T細胞銜接器2.0平台，具有「 ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

Core Insights - Anqing is undergoing a transformation driven by innovation, aiming to establish itself as a strong industrial city while integrating cultural tourism into its development strategy [1][29] Economic Performance - Anqing's GDP is projected to exceed 310 billion yuan in 2024, with 7 out of 29 major economic indicators ranking in the top three in the province [3] - High-tech manufacturing investment grew by 12.4% in the first half of 2025, ranking third in the province, while industrial technological transformation investment increased by 10.8% [3] Industrial Transformation - Anqing has been recognized as one of the top 100 advanced manufacturing cities in China for four consecutive years, with an output value surpassing 260 billion yuan [3] - The city is focusing on innovation-driven development, establishing a comprehensive policy system to support industries such as new energy vehicles and chemical new materials [6][7] Innovation Platforms - During the "14th Five-Year Plan" period, Anqing created numerous innovation platforms, including one national-level enterprise technology center and 11 provincial engineering research centers [7] - The city has established 152 provincial-level innovation platforms in the automotive and chemical industries, securing 550 million yuan in policy funding [7] Emerging Industries - Anqing is actively developing strategic emerging industries, with 615 new enterprises in this sector, accounting for 41.8% of the industrial output value [13] - The city is also making strides in commercial aerospace, biotechnology, and hydrogen energy, with plans to establish over 30 commercial aerospace projects by 2027 [15][16] Cultural Tourism Development - Anqing is leveraging its rich cultural heritage to enhance tourism, with 175 cultural enterprises generating 4.41 billion yuan in revenue and attracting 61.89 million domestic tourists [19] - The city is revitalizing historical districts and integrating modern experiences with traditional culture to create a vibrant tourism ecosystem [21][24] Strategic Vision - Anqing's approach combines historical legacy with future-oriented development, showcasing a model for the transformation of old industrial cities [29]

Core Insights - Two stock ETFs have recently announced their listing, with the latest positions showing a stock position of 30.14% for the Bosera CSI Bank ETF and 10.19% for the Hong Kong Stock Connect Technology ETF [1][2] - In the past month, a total of 26 stock ETFs have announced their listings, with an average position of only 20.04%. The highest position is held by the Morgan Stanley Hang Seng Hong Kong Stock Connect 50 ETF at 54.00% [1][3] - The average fundraising for the newly announced ETFs is 449 million shares, with the leading funds being the China Merchants National Index Hong Kong Stock Connect Technology ETF, the Harvest CSI Sub-Sector Chemical Industry Theme ETF, and the Penghua Hang Seng Biotechnology ETF, with shares of 935 million, 926 million, and 758 million respectively [1][2] ETF Positioning - The Bosera CSI Bank ETF has a stock position of 30.14% and is set to be listed on December 8, 2025, after a fundraising of 203 million shares [2] - The Hong Kong Stock Connect Technology ETF has a stock position of 10.19% and is scheduled for listing on December 8, 2025, with a fundraising of 318 million shares [2] - The Morgan Stanley Hang Seng Hong Kong Stock Connect 50 ETF has the highest stock position at 54.00% and is expected to be listed on November 25, 2025 [3] Institutional Investor Holdings - The average shareholding of institutional investors across these ETFs is 10.55%, with the highest being the Guolian An Hong Kong Stock Connect Technology ETF at 31.99% [2] - Other ETFs with significant institutional holdings include the Huabao CSI Hong Kong Stock Connect Information Technology Comprehensive ETF at 29.99% and the Bosera CSI Bank ETF at 22.72% [2] - Conversely, the Tianhong National Index Hong Kong Stock Connect Technology ETF and the E Fund CSI A500 Dividend Low Volatility ETF have very low institutional holdings at 0.59% and 2.91% respectively [2]

然而，今年9月，一场罕见的"烂场雨"让企业受到不小冲击。"当时在仓库里存放了1200多吨原料，持续 降雨导致地势本就较低的仓库进水，大量原料发霉变质，一部分成品过水霉变，企业直接受损100多万 元。"崔文斌回想起当时的情景仍心有余悸。 彼时，该公司还新投资了生产设备，在多重压力下，流动资金出现了缺口。于是，崔文斌和公司负责人 武飞阳四处筹钱，以期快速恢复生产。 中原银行汝州市支行了解到这一情况后，第一时间对接河南省农业信贷担保有限责任公司（以下简称省 农担公司），实地走访考察企业受灾情况，并为其推荐了"救灾贷"。 来源：环球网 近日，和煦的阳光洒向大地，虽已入冬，但仍暖意融融。这几天，河南汝州中农翱翔生物科技有限公司 生产经理崔文斌格外高兴。中原银行平顶山分行的200万元"救灾贷"到账了，企业稳产扩产有了底气， 萦绕心头多日的阴霾也随之驱散。 该公司位于汝州经济技术开发区，是一家专攻生物发酵技术研发与生产的科技型企业，自主研发的营养 菌、发酵蛋白饲料等产品，主要用于农作物、畜牧养殖、水产养殖等行业，产品远销全国20多个省市， 年营业额达3000余万元，企业规模位居全国前列。 走进公司仓库内，规格不同的饲料添加 ...

Group 1 - The core point of the article is that Guanhao Biological has established a subsidiary, Beijing Tianyou Qiyuan Biotechnology Co., Ltd., in March 2025 as part of its strategic development and business planning [2] Group 2 - The establishment of the subsidiary is aligned with the company's operational needs [2]

医药板块今日回调，截至收盘，中证港股通医药卫生综合指数下跌1.3%，恒生港股通创新药指数下跌1.4%，沪深300医药卫生指数下跌1.5%，中证创新药产 业指数下跌1.6%，中证生物科技主题指数下跌1.8%。 华创证券称，医药行业能在持续经历各种挑战后走向新高最本质的原因，是人类对医药行业的持续需求和越来越多的未被满足的需求，以及药企不断持续加 大研发投入去满足这些需求。中国如今已成为全球创新药研发的重要参与者，海外授权热度持续连年攀升，医药行业进入"创新驱动"的营收时代。 比较坏十川上的一个一个百人 该指数聚焦A股创新药龙头, 由不超过50只主营业务涉 及创新药研发的公司股票 组成,汇聚A股创新药主力 车。 | 今日 | 该指数 | 该指数自201 | | --- | --- | --- | | 该指数涨跌 | 滚动市盈率 | 发布以来估值 | | -1.6% | 50.2倍 | 72.8% | 医药ETF 唯一 跟踪沪深300医药卫生指数 该指数聚焦A股医药卫生行 业龙头,由沪深300指数样 本中属于医药卫生行业的公 司股票组成,全面覆盖化学 制药、医疗服务、医疗器械 等未来健康产业细分环节。 该指数自20 ...

董事会认为，当前股价低于公司内在价值，未充分反映业务前景及资产价值，回购计划符合公司及股东 整体最佳利益，是资本管理及优化资本结构的有效措施。回购计划将遵守相关法规及授权，购回股份将 适时予以注销及/或持作库存股份。 智通财经APP获悉，巨子生物(02367)午后涨超6%，截至发稿，涨6.12%，报38.84港元，成交额3.76亿港 元。 消息面上，巨子生物午间公告，其计划行使回购股份授权，以购回公司股份。根据回购股份授权，公司 获准购回不超过1.036亿股股份，即已发行股份数目(不包括库存股份)的10%。 ...

Core Insights - The People's Bank of China (PBOC) is enhancing support for the real economy in Changde, focusing on key industries such as advanced equipment manufacturing, biomedicine, electronic information, and new materials, aiming for stable credit growth [1] Group 1: Credit Support and Economic Growth - In the first nine months of 2025, banks in Changde issued a total of 98.3 billion yuan in corporate loans, an increase of 20.4 billion yuan year-on-year, with total loans in the city surpassing 400 billion yuan [1] - The GDP of Changde reached 340.39 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 5.9%, ranking among the top in the province [1] Group 2: Cost Reduction for Enterprises - The PBOC's reduction of structural monetary policy tool rates by 0.25 percentage points has led to significant cost savings for banks and enterprises, with estimated savings of over 7 million yuan in loan costs for agricultural and small enterprises in Changde [2] - By the end of September 2025, the average weighted interest rate for corporate loans in Changde decreased by 40 basis points year-on-year, resulting in over 1.3 billion yuan in fee reductions for various market entities [2] Group 3: Financing Transparency and Support for SMEs - Changde was included in the second batch of pilot cities for comprehensive financing cost transparency, with 4,539 loans totaling 29.66 billion yuan completed by the end of September 2025, leading to a 60 basis point reduction in comprehensive financing rates [3] Group 4: Financial Tools and Structural Optimization - The PBOC's initiatives have led to a significant increase in technology innovation and technical transformation loans, with 990 million yuan signed and 620 million yuan disbursed by the end of September 2025 [4] - Green loans in Changde reached a balance of 77.37 billion yuan, with an increase of 14.9 billion yuan, representing a growth rate of 23.9% [4] Group 5: Support for Agriculture and Small Enterprises - Since the beginning of 2025, the PBOC has issued 6.82 billion yuan in re-loans and rediscounting for agriculture and small enterprises, an increase of 2.44 billion yuan year-on-year, facilitating an additional 3.89 billion yuan in inclusive small loans [5] Group 6: Consumer Services and Elderly Care Financing - The PBOC is promoting service consumption and elderly care financing through innovative loan products tailored to specific needs, enhancing the quality of financial services in these sectors [6] Group 7: Industry Empowerment and Financial Innovation - The PBOC is facilitating the development of a modern industrial system in Changde by establishing a collaborative mechanism with local authorities and banks, resulting in a loan balance of 4.58 billion yuan for emerging industries, a year-on-year increase of 18.7% [7] Group 8: Support for Technology and Small Enterprises - Local banks are innovating financial products such as "synthetic biology loans" and "order loans" to support small and medium-sized enterprises, with a total of 2.82 billion yuan allocated to 160 SMEs [8] - By the end of September 2025, the balance of technology loans in Changde reached 50.62 billion yuan, reflecting a year-on-year growth of 12.7% [8]